Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Jan;90(1):27-30.
doi: 10.1002/ajh.23858. Epub 2014 Oct 18.

Improving outcomes for patients with acute myeloid leukemia in first relapse: a single center experience

Naveen Pemmaraju  1 , Hagop Kantarjian, Guillermo Garcia-Manero, Sherry Pierce, Marylou Cardenas-Turanzas, Jorge Cortes, Farhad Ravandi
Affiliations

Improving outcomes for patients with acute myeloid leukemia in first relapse: a single center experience

Naveen Pemmaraju et al. Am J Hematol. 2015 Jan.

Abstract

The outcome of patients with relapsed acute myeloid leukemia (AML) remains unsatisfactory, with few available effective therapies. Increased understanding of the biology of the disease has led to the identification of novel therapeutic agents, several of which have been evaluated in recently conducted clinical trials. We sought to determine whether the introduction of these agents as well as modern supportive care measures has already translated to better outcomes. We examined the outcomes of 1,056 patients with AML in first relapse treated between January 1993 and December 2013 at our institution. As previously reported, the independent prognostic factors for survival after first relapse included age at relapse, cytogenetics, and duration of first complete remission. Upon multivariable analysis, treatment era was an independent predictor of survival, with significant improvement in overall survival between 2008 and 2013 as compared to prior time periods. Modern supportive care measures as well as participation in clinical trials of novel agents are already improving the outcomes in first relapse.

PubMed Disclaimer

Conflict of interest statement

Conflicts/Disclosures: The authors have no disclosures or conflicts of interest with regards to this manuscript.

Figures

Figure 1
Figure 1
a: Overall Survival, by Earliest and Most Recent Treatment Era b: Overall Survival, by Treatment Era
Figure 1
Figure 1
a: Overall Survival, by Earliest and Most Recent Treatment Era b: Overall Survival, by Treatment Era
See this image and copyright information in PMC

References

    1. Burnett A, Wetzler M, Lowenberg B. Therapeutic advances in acute myeloid leukemia. J Clin Oncol. 2011;29:487–94. - PubMed
    1. Keating MJ, Kantarjian H, Smith TL, et al. Response to salvage therapy and survival after relapse in acute myelogenous leukemia. J Clin Oncol. 1989;7:1071–80. - PubMed
    1. Estey E, Kornblau S, Pierce S, Kantarjian H, Beran M, Keating M. A stratification system for evaluating and selecting therapies in patients with relapsed or primary refractory acute myelogenous leukemia. Blood. 1996;88:756. - PubMed
    1. Estey EH. Treatment of relapsed and refractory acute myelogenous leukemia. Leukemia. 2000;14:476–9. - PubMed
    1. Ravandi F, Cortes J, Faderl S, et al. Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy. Blood. 2010;116:5818–23. quiz 6153. - PMC - PubMed

Publication types

MeSH terms

Substances